TrialBlood advances2018

Denosumab in transfusion-dependent thalassemia osteoporosis: a randomized, placebo-controlled, double-blind phase 2b clinical trial.

Ersi Voskaridou et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.